Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422911 · ClinicalTrials.gov registry record · Phase 2
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT05422911 is a Phase 2 study that is actively recruiting participants, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 192 participants.
The verdict
NCT05422911, a Phase 2 study, is actively recruiting participants, sponsored by Sun Pharmaceutical Industries Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA the treatment of prostate cancer is excellent and uniform across the US. The choices made are clearly personalized, given not all men received all therapies and that younger Veterans were treated more aggressively. But with survivals that rival those in registration trials that enroll optimally fit individuals usually not encumbered by the co-morbidities that afflict many Veterans, the outcomes are testimony to the fact that for this common malady of older Veterans with whom VA physicians have broad experience the care administered is unsurpassed. Importantly this care at least as regards Veterans with mCRPC demonstrates that given equal access to health care, all men with prostate cancer fare comparably well. As our sophistication in categorizing cancers molecularly has increased this study will look to better examine any emerging differences across study participants.
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05422911
The ClinicalTrials.gov registry entry for NCT05422911 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Apalutamide is the first listed.
NCT05422911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05422911 about?
NCT05422911 is a clinical study titled "Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.". The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings s...
What is the current status of trial NCT05422911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2022-08-31. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05422911?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT05422911?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.